Drugs / Allogeneic DCs and Autologous RCC Tumor Derived Cells
Allogeneic DCs and Autologous RCC Tumor Derived Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00050323 | Nov 2002 → Mar 2004 | renal cell carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic DCs and Autologous RCC Tumor Derived Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00050323 ↗ |
| Modality | Cell therapy | “The fused dendritic/tumor cells will be returned to the patient in a series of vaccines, six weeks apart.” NCT00050323 ↗ |
| Route | Other | “The primary purpose of this study is to determine the safety of injections prepared from donor blood cells fused to a patient's own tumor cells” NCT00050323 ↗ |